Peera Hemarajata
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Peera Hemarajata has a total of 143 co-authors. Here are the top co-authors by number of shared publications:
- Romney M. Humphries
Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, UCLA, Los Angeles, California, USA
8 shared publications - James Versalovic
Baylor College of Medicine
6 shared publications Shangxin Yang
Department of Pathology, University of New Mexico, Albuquerque, NM 87131, USA
5 shared publicationsMoon Kim
Los Angeles County Department of Public Health , Downey, California, USA
4 shared publicationsAmy N. Marutani
Los Angeles County Department of Public Health , Downey, California, USA
3 shared publications- Carissa M. Thomas
Department of Otolaryngology University of Alabama at Birmingham Birmingham Alabama USA
3 shared publications
Latest Publications
- Open Access
- 3 November 2026
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 14 (11)
Genomic characteristics of the first five monkeypox virus clade Ib cases in Thailand: August 2024–March 2025
Following the emergence of monkeypox virus clade Ib in the Democratic Republic of the Congo in August 2024, the World Health Organization declared a public health emergency of international concern because of sustained transmission and international spread. We characterized the first clade Ib cases detected in Thailand between August 2024 and March 2025 and assessed their phylogenetic relationships. Whole-genome sequencing was performed from lesion swabs of suspected cases. Phylogenetic analysis, incorporating clade Ia ( DQ011155.1 ) and global clade Ib sequences from GISAID, confirmed all Thai isolates as clade Ib. The genomes showed close relatedness to clade Ib viruses reported internationally, consistent with patients’ travel histories. All isolates exhibited a 1,140-bp deletion in the C3L gene region and 52–61 amino acid substitutions compared with the clade Ia reference. Genome sequences were submitted to GISAID and NCBI to support outbreak response and improve understanding of epidemiologic patterns, enabling more effective public health interventions. IMPORTANCE: On 14 August 2024, the World Health Organization declared the monkeypox virus outbreak in Africa a public health emergency of international concern following the emergence of clade Ib. One week later, Thailand confirmed the first monkeypox clade Ib case in Asia. Through whole-genome sequencing and phylogenomic analysis of five cases detected between August 2024 and March 2025, we identified a 1,140-bp deletion in the C3L gene region that distinguishes clade Ib from clade Ia. This deletion directly affects the performance of some commercial real-time PCR assays designed for clade Ia, which rely on amplification of the missing genomic region. Our findings highlight important diagnostic limitations that could lead to misinterpretation or reduced sensitivity in routine testing. Beyond confirming regional introduction linked to global spread, this study underscores the critical role of genomic surveillance in ensuring accurate diagnosis, monitoring viral evolution, and strengthening outbreak response as monkeypox continues to expand internationally.
- 3 November 2026
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 14 (11)
Open AccessGenomic characteristics of the first five monkeypox virus clade Ib cases in Thailand: August 2024–March 2025
Following the emergence of monkeypox virus clade Ib in the Democratic Republic of the Congo in August 2024, the World Health Organization declared a public health emergency of international concern because of sustained transmission and international spread. We characterized the first clade Ib cases detected in Thailand between August 2024 and March 2025 and assessed their phylogenetic relationships. Whole-genome sequencing was performed from lesion swabs of suspected cases. Phylogenetic analysis, incorporating clade Ia ( DQ011155.1 ) and global clade Ib sequences from GISAID, confirmed all Thai isolates as clade Ib. The genomes showed close relatedness to clade Ib viruses reported internationally, consistent with patients’ travel histories. All isolates exhibited a 1,140-bp deletion in the C3L gene region and 52–61 amino acid substitutions compared with the clade Ia reference. Genome sequences were submitted to GISAID and NCBI to support outbreak response and improve understanding of epidemiologic patterns, enabling more effective public health interventions. IMPORTANCE: On 14 August 2024, the World Health Organization declared the monkeypox virus outbreak in Africa a public health emergency of international concern following the emergence of clade Ib. One week later, Thailand confirmed the first monkeypox clade Ib case in Asia. Through whole-genome sequencing and phylogenomic analysis of five cases detected between August 2024 and March 2025, we identified a 1,140-bp deletion in the C3L gene region that distinguishes clade Ib from clade Ia. This deletion directly affects the performance of some commercial real-time PCR assays designed for clade Ia, which rely on amplification of the missing genomic region. Our findings highlight important diagnostic limitations that could lead to misinterpretation or reduced sensitivity in routine testing. Beyond confirming regional introduction linked to global spread, this study underscores the critical role of genomic surveillance in ensuring accurate diagnosis, monitoring viral evolution, and strengthening outbreak response as monkeypox continues to expand internationally.
- 15 November 2023
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 67 (11) , e0097223
Community spread of a human monkeypox virus variant with a tecovirimat resistance-associated mutation
- 15 November 2023
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 67 (11) , e0097223
Community spread of a human monkeypox virus variant with a tecovirimat resistance-associated mutation
- 18 July 2023
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 67 (7) , e0056823
Identification of Tecovirimat Resistance-Associated Mutations in Human Monkeypox Virus - Los Angeles County
- 18 July 2023
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 67 (7) , e0056823
Identification of Tecovirimat Resistance-Associated Mutations in Human Monkeypox Virus - Los Angeles County
- 30 March 2023
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 388 (13) , 1246-1247
An Mpox-Related Death in the United States
- 30 March 2023
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 388 (13) , 1246-1247
An Mpox-Related Death in the United States
- 21 December 2022
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 60 (12) , e0165522
Identification of Human Monkeypox Virus Genome Deletions That Impact Diagnostic Assays
- 21 December 2022
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 60 (12) , e0165522
Identification of Human Monkeypox Virus Genome Deletions That Impact Diagnostic Assays
- Open Access
- 1 September 2018
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 62 (9)
Variability of Daptomycin MIC Values for Enterococcus faecium When Measured by Reference Broth Microdilution and Gradient Diffusion Tests
Daptomycin has become a mainstay therapy for the treatment of serious vancomycin-resistant Enterococcus faecium infections. However, concern exists that current testing methods do not accurately predict clinical success of daptomycin therapy. We evaluated a collection of 40 isolates of E. faecium across 3 centers by reference broth microdilution (BMD), and two gradient strips, to determine the precision of daptomycin MICs by these methods and the correlation of daptomycin MIC testing with mutations in the liaFSR system, one of the primary daptomycin resistance mechanisms among the enterococci. Daptomycin MICs spanned 3 log2 dilutions by BMD for 60.0% of isolates, 17.5% spanned 4 dilutions, 2.5% spanned 5 dilutions, and 20.0% spanned 6 or more dilutions. Fifteen isolates had MICs interpreted as susceptible by some tests, and nonsusceptible by others. Neither BMD not gradient diffusion tests could reliably differentiate isolates with or without mutations in liaFSR, resulting in a 59.8% very major error rate compared to genotype by BMD, 63.5% by Etest and 68.5% by MIC Test Strip. Imprecision in daptomycin MIC determination for E. faecium make establishment of a revised breakpoint challenging. Clinicians should be aware of this testing variability when making treatment decisions for patients with serious infections caused by this organism.
- 1 September 2018
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 62 (9)
Open AccessVariability of Daptomycin MIC Values for Enterococcus faecium When Measured by Reference Broth Microdilution and Gradient Diffusion Tests
Daptomycin has become a mainstay therapy for the treatment of serious vancomycin-resistant Enterococcus faecium infections. However, concern exists that current testing methods do not accurately predict clinical success of daptomycin therapy. We evaluated a collection of 40 isolates of E. faecium across 3 centers by reference broth microdilution (BMD), and two gradient strips, to determine the precision of daptomycin MICs by these methods and the correlation of daptomycin MIC testing with mutations in the liaFSR system, one of the primary daptomycin resistance mechanisms among the enterococci. Daptomycin MICs spanned 3 log2 dilutions by BMD for 60.0% of isolates, 17.5% spanned 4 dilutions, 2.5% spanned 5 dilutions, and 20.0% spanned 6 or more dilutions. Fifteen isolates had MICs interpreted as susceptible by some tests, and nonsusceptible by others. Neither BMD not gradient diffusion tests could reliably differentiate isolates with or without mutations in liaFSR, resulting in a 59.8% very major error rate compared to genotype by BMD, 63.5% by Etest and 68.5% by MIC Test Strip. Imprecision in daptomycin MIC determination for E. faecium make establishment of a revised breakpoint challenging. Clinicians should be aware of this testing variability when making treatment decisions for patients with serious infections caused by this organism.
- 19 February 2018
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 73 (5) , 1256-1262
Selection of hyperproduction of AmpC and SME-1 in a carbapenem-resistant Serratia marcescens isolate during antibiotic therapy
Antibiotic selective pressure may result in changes to antimicrobial susceptibility throughout the course of infection, especially for organisms that harbour chromosomally encoded AmpC β-lactamases, notably Enterobacter spp., in which hyperexpression of ampC may be induced following treatment with cephalosporins. In this study, we document a case of bacteraemia caused by a blaSME-1-harbouring Serratia marcescens that subsequently developed resistance to expanded-spectrum cephalosporins, piperacillin/tazobactam and fluoroquinolones, over the course of several months of treatment with piperacillin/tazobactam and ciprofloxacin. Susceptibility testing and WGS were performed on three S. marcescens isolates from the patient. β-Lactamase activity in the presence or absence of induction by imipenem was measured by nitrocefin hydrolysis assays. Expression of ampC and blaSME-1 under the same conditions was determined by real-time PCR. WGS demonstrated accumulation of missense and nonsense mutations in ampD associated with stable derepression of AmpC. Gene expression and β-lactamase activity of both AmpC and SME-1 were inducible in the initial susceptible isolate, but were constitutively high in the resistant isolate, in which total β-lactamase activity was increased by 128-fold. Although development of such in vitro resistance due to selective pressure imposed by antibiotics is reportedly low in S. marcescens, our findings highlight the need to evaluate isolates on a regular basis during long-term antibiotic therapy.
- 19 February 2018
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 73 (5) , 1256-1262
Selection of hyperproduction of AmpC and SME-1 in a carbapenem-resistant Serratia marcescens isolate during antibiotic therapy
Antibiotic selective pressure may result in changes to antimicrobial susceptibility throughout the course of infection, especially for organisms that harbour chromosomally encoded AmpC β-lactamases, notably Enterobacter spp., in which hyperexpression of ampC may be induced following treatment with cephalosporins. In this study, we document a case of bacteraemia caused by a blaSME-1-harbouring Serratia marcescens that subsequently developed resistance to expanded-spectrum cephalosporins, piperacillin/tazobactam and fluoroquinolones, over the course of several months of treatment with piperacillin/tazobactam and ciprofloxacin. Susceptibility testing and WGS were performed on three S. marcescens isolates from the patient. β-Lactamase activity in the presence or absence of induction by imipenem was measured by nitrocefin hydrolysis assays. Expression of ampC and blaSME-1 under the same conditions was determined by real-time PCR. WGS demonstrated accumulation of missense and nonsense mutations in ampD associated with stable derepression of AmpC. Gene expression and β-lactamase activity of both AmpC and SME-1 were inducible in the initial susceptible isolate, but were constitutively high in the resistant isolate, in which total β-lactamase activity was increased by 128-fold. Although development of such in vitro resistance due to selective pressure imposed by antibiotics is reportedly low in S. marcescens, our findings highlight the need to evaluate isolates on a regular basis during long-term antibiotic therapy.
- 1 November 2017
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 61 (11)
Real-Time PCR Targeting the penA Mosaic XXXIV Type for Prediction of Extended-Spectrum-Cephalosporin Susceptibility in Clinical Neisseria gonorrhoeae Isolates
Neisseria gonorrhoeae isolates with decreased susceptibility to extended-spectrum cephalosporins (ESCs) are increasing. We developed an assay to predict N. gonorrhoeae susceptibility to ESCs by targeting penA mosaic XXXIV, an allele prevalent among U.S. isolates with elevated ESC MICs. The assay was 97% sensitive and 100% specific for predicting at least one ESC MIC above the CDC alert value among clinical isolates, and it could be multiplexed with a previously validated gyrA PCR to predict ciprofloxacin susceptibility.
- 1 November 2017
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 61 (11)
Real-Time PCR Targeting the penA Mosaic XXXIV Type for Prediction of Extended-Spectrum-Cephalosporin Susceptibility in Clinical Neisseria gonorrhoeae Isolates
Neisseria gonorrhoeae isolates with decreased susceptibility to extended-spectrum cephalosporins (ESCs) are increasing. We developed an assay to predict N. gonorrhoeae susceptibility to ESCs by targeting penA mosaic XXXIV, an allele prevalent among U.S. isolates with elevated ESC MICs. The assay was 97% sensitive and 100% specific for predicting at least one ESC MIC above the CDC alert value among clinical isolates, and it could be multiplexed with a previously validated gyrA PCR to predict ciprofloxacin susceptibility.
- Open Access
- 1 October 2017
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 61 (10) , e00989-17
Resistance to Ceftazidime-Avibactam Is Due to Transposition of KPC in a Porin-Deficient Strain of Klebsiella pneumoniae with Increased Efflux Activity
Ceftazidime-avibactam is an antibiotic with activity against serine beta-lactamases, including Klebsiella pneumoniae carbapenemase (KPC). Recently, reports have emerged of KPC-producing isolates resistant to this antibiotic, including a report of a wild-type KPC-3 producing sequence type 258 Klebsiella pneumoniae that was resistant to ceftazidime-avibactam. We describe a detailed analysis of this isolate, in the context of two other closely related KPC-3 producing isolates, recovered from the same patient. Both isolates encoded a nonfunctional OmpK35, whereas we demonstrate that a novel T333N mutation in OmpK36, present in the ceftazidime-avibactam resistant isolate, reduced the activity of this porin and impacted ceftazidime-avibactam susceptibility. In addition, we demonstrate that the increased expression of bla KPC-3 and bla SHV-12 observed in the ceftazidime-avibactam-resistant isolate was due to transposition of the Tn 4401 transposon harboring bla KPC-3 into a second plasmid, pIncX3, which also harbored bla SHV-12 , ultimately resulting in a higher copy number of bla KPC -3 in the resistant isolate. pIncX3 plasmid from the ceftazidime-avibactam resistant isolate, conjugated into a OmpK35/36-deficient K. pneumoniae background that harbored a mutation to the ramR regulator of the acrAB efflux operon recreated the ceftazidime-avibactam-resistant MIC of 32 μg/ml, confirming that this constellation of mutations is responsible for the resistance phenotype.
- 1 October 2017
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 61 (10) , e00989-17
Open AccessResistance to Ceftazidime-Avibactam Is Due to Transposition of KPC in a Porin-Deficient Strain of Klebsiella pneumoniae with Increased Efflux Activity
Ceftazidime-avibactam is an antibiotic with activity against serine beta-lactamases, including Klebsiella pneumoniae carbapenemase (KPC). Recently, reports have emerged of KPC-producing isolates resistant to this antibiotic, including a report of a wild-type KPC-3 producing sequence type 258 Klebsiella pneumoniae that was resistant to ceftazidime-avibactam. We describe a detailed analysis of this isolate, in the context of two other closely related KPC-3 producing isolates, recovered from the same patient. Both isolates encoded a nonfunctional OmpK35, whereas we demonstrate that a novel T333N mutation in OmpK36, present in the ceftazidime-avibactam resistant isolate, reduced the activity of this porin and impacted ceftazidime-avibactam susceptibility. In addition, we demonstrate that the increased expression of bla KPC-3 and bla SHV-12 observed in the ceftazidime-avibactam-resistant isolate was due to transposition of the Tn 4401 transposon harboring bla KPC-3 into a second plasmid, pIncX3, which also harbored bla SHV-12 , ultimately resulting in a higher copy number of bla KPC -3 in the resistant isolate. pIncX3 plasmid from the ceftazidime-avibactam resistant isolate, conjugated into a OmpK35/36-deficient K. pneumoniae background that harbored a mutation to the ramR regulator of the acrAB efflux operon recreated the ceftazidime-avibactam-resistant MIC of 32 μg/ml, confirming that this constellation of mutations is responsible for the resistance phenotype.
- 25 September 2017
- Published by Wiley in Pediatric Dermatology
- Vol. 34 (6) , 665-667
Pediatric vaccine‐strain herpes zoster: a case series
Background/objectives: Herpes zoster (HZ) is caused by reactivation of the varicella zoster virus (VZV), and typically causes a painful, vesicular, dermatomal rash in adults over the age of fifty. However, HZ has been known to present in immunocompetent pediatric patients, which account for under 1% of total cases. Pediatric cases are typically caused by natural infection with VZV, but among vaccinated children up to half of cases can be due to vaccine‐strain VZV. We present two such cases of vaccine‐strain HZ in pediatric patients.Methods: This is a retrospective study of two cases seen at UCLA‐affiliated sites. PCR and Sanger sequencing, using previously described PCR primers, determined the presence of two vaccine‐strain‐specific single nucleotide polymorphisms.Results: We report two cases of vaccine‐strain HZ in immunocompetent pediatric patients who had previously received the varicella vaccine, affecting the right thigh in the first patient and the left leg in the second. Varicella‐strain VZV positivity was confirmed by PCR. Both patients had received the varicella vaccine at 12 months of age. Both patients achieved complete resolution of symptoms after 7‐day courses of acyclovir.Conclusions: While vaccination against VZV has overall reduced the incidence of both varicella and HZ in US children, given the widespread use of the VZV vaccine, awareness of the possibility of vaccine‐induced HZ remains an important consideration.
- 25 September 2017
- Published by Wiley in Pediatric Dermatology
- Vol. 34 (6) , 665-667
Pediatric vaccine‐strain herpes zoster: a case series
Background/objectives: Herpes zoster (HZ) is caused by reactivation of the varicella zoster virus (VZV), and typically causes a painful, vesicular, dermatomal rash in adults over the age of fifty. However, HZ has been known to present in immunocompetent pediatric patients, which account for under 1% of total cases. Pediatric cases are typically caused by natural infection with VZV, but among vaccinated children up to half of cases can be due to vaccine‐strain VZV. We present two such cases of vaccine‐strain HZ in pediatric patients.Methods: This is a retrospective study of two cases seen at UCLA‐affiliated sites. PCR and Sanger sequencing, using previously described PCR primers, determined the presence of two vaccine‐strain‐specific single nucleotide polymorphisms.Results: We report two cases of vaccine‐strain HZ in immunocompetent pediatric patients who had previously received the varicella vaccine, affecting the right thigh in the first patient and the left leg in the second. Varicella‐strain VZV positivity was confirmed by PCR. Both patients had received the varicella vaccine at 12 months of age. Both patients achieved complete resolution of symptoms after 7‐day courses of acyclovir.Conclusions: While vaccination against VZV has overall reduced the incidence of both varicella and HZ in US children, given the widespread use of the VZV vaccine, awareness of the possibility of vaccine‐induced HZ remains an important consideration.